<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34878988</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.</ArticleTitle><Pagination><StartPage>e28021</StartPage><MedlinePgn>e28021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/28021</ELocationID><Abstract><AbstractText Label="BACKGROUND">Researchers face challenges in patient recruitment, especially for rare, fatal diseases such as amyotrophic lateral sclerosis (ALS). These challenges include obtaining sufficient statistical power as well as meeting eligibility requirements such as age, sex, and study proximity. Similarly, persons with ALS (PALS) face difficulty finding and enrolling in research studies for which they are eligible.</AbstractText><AbstractText Label="OBJECTIVE">The aim of this study was to describe how the federal Agency for Toxic Substances and Disease Registry's (ATSDR) National ALS Registry is linking PALS to scientists who are conducting research, clinical trials, and epidemiological studies.</AbstractText><AbstractText Label="METHODS">Through the Registry's online research notification mechanism (RNM), PALS can elect to be notified about new research opportunities. This mechanism allows researchers to upload a standardized application outlining their study design and objectives, and proof of Institutional Review Board approval. If the application is approved, ATSDR queries the Registry for PALS meeting the study's specific eligibility criteria, and then distributes the researcher's study material and contact information to PALS via email. PALS then need to contact the researcher directly to take part in any research. Such an approach allows ATSDR to protect the confidentiality of Registry enrollees.</AbstractText><AbstractText Label="RESULTS">From 2013 to 2019, a total of 46 institutions around the United States and abroad have leveraged this tool and over 600,000 emails have been sent, resulting in over 2000 patients conservatively recruited for clinical trials and epidemiological studies. Patients between the ages of 60 and 69 had the highest level of participation, whereas those between the ages of 18 and 39 and aged over 80 had the lowest. More males participated (4170/7030, 59.32%) than females (2860/7030, 40.68%).</AbstractText><AbstractText Label="CONCLUSIONS">The National ALS Registry's RNM benefits PALS by connecting them to appropriate ALS research. Simultaneously, the system benefits researchers by expediting recruitment, increasing sample size, and efficiently identifying PALS meeting specific eligibility requirements. As more researchers learn about and use this mechanism, both PALS and researchers can hasten research and expand trial options for PALS.</AbstractText><CopyrightInformation>&#xa9;Paul Mehta, Jaime Raymond, Moon Kwon Han, Theodore Larson, James D Berry, Sabrina Paganoni, Hiroshi Mitsumoto, Richard Stanley Bedlack, D Kevin Horton. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 07.12.2021.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0796-8861</Identifier><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymond</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5594-6931</Identifier><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Moon Kwon</ForeName><Initials>MK</Initials><Identifier Source="ORCID">0000-0002-2246-3618</Identifier><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Theodore</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-4719-4829</Identifier><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berry</LastName><ForeName>James D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0003-0898-6081</Identifier><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paganoni</LastName><ForeName>Sabrina</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0505-1168</Identifier><AffiliationInfo><Affiliation>Sean M Healey &amp; AMG Center for ALS, Massachusetts General Hospital, Boston, MA, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, MA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitsumoto</LastName><ForeName>Hiroshi</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-6259-8923</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Columbia University College of Physicians and Surgeons, New York City, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard Stanley</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0003-4666-7495</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Duke University School of Medicine, Durham, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horton</LastName><ForeName>D Kevin</ForeName><Initials>DK</Initials><Identifier Source="ORCID">0000-0001-6214-6687</Identifier><AffiliationInfo><Affiliation>Agency for Toxic Substances and Disease Registry, Centers for Disease Control and Prevention, Atlanta, GA, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016021" MajorTopicYN="N">Epidemiologic Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lou Gehrig disease</Keyword><Keyword MajorTopicYN="N">National ALS Registry</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">motor neuron disease</Keyword><Keyword MajorTopicYN="N">patient recruitment</Keyword><Keyword MajorTopicYN="N">research notification mechanism</Keyword></KeywordList><CoiStatement>Conflicts of Interest: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>4</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>8</Day><Hour>17</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34878988</ArticleId><ArticleId IdType="pmc">PMC8693186</ArticleId><ArticleId IdType="doi">10.2196/28021</ArticleId><ArticleId IdType="pii">v23i12e28021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chi&#xf2; A, Logroscino G, Traynor BJ, Collins J, Simeone JC, Goldstein LA, White LA. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology. 2013;41(2):118&#x2013;30. doi: 10.1159/000351153. 
 
000351153</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, Muravov O, Horton K. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. 2018 Nov 23;67(46):1285&#x2013;1289. doi: 10.15585/mmwr.mm6746a1. doi: 10.15585/mmwr.mm6746a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm6746a1</ArticleId><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsumoto H, Chad DA, Pioro EP. Amyotrophic Lateral Sclerosis. Philadelphia, PA: A F. A. Davis Company; 1998. Jan 02,</Citation></Reference><Reference><Citation>Eisen A. Amyotrophic lateral sclerosis is a multifactorial disease. Muscle Nerve. 1995 Jul;18(7):741&#x2013;52. doi: 10.1002/mus.880180711.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.880180711</ArticleId><ArticleId IdType="pubmed">7783764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhandari R, Kuhad A, Kuhad A. Edaravone: a new hope for deadly amyotrophic lateral sclerosis. Drugs Today (Barc) 2018 Jun;54(6):349&#x2013;360. doi: 10.1358/dot.2018.54.6.2828189.2828189</Citation><ArticleIdList><ArticleId IdType="doi">10.1358/dot.2018.54.6.2828189</ArticleId><ArticleId IdType="pubmed">29998226</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Kiernan MC. Riluzole, disease stage and survival in ALS. Lancet Neurol. 2018 May;17(5):385&#x2013;386. doi: 10.1016/S1474-4422(18)30091-7. 
 
S1474-4422(18)30091-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30091-7</ArticleId><ArticleId IdType="pubmed">29525493</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS Registry Act Public Law. 2008.  [2021-01-01].  
 https://www.cdc.gov/als/ALSRegistryActPublicLaw.html
.</Citation></Reference><Reference><Citation>Mehta P, Antao V, Kaye W, Sanchez M, Williamson D, Bryan L, Muravov O, Horton K. Prevalence of amyotrophic lateral sclerosis - United States, 2010-2011. MMWR Suppl. 2014 Jul 25;63(7):1&#x2013;14.ss6307a1</Citation><ArticleIdList><ArticleId IdType="pubmed">25054277</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Yerramilli-Rao P, Szymonifka J, Yu H, Kearney M, Grasso D, Deng J, Levine-Weinberg M, Shapiro J, Lee A, Joseph L, Macklin EA, Cudkowicz ME. Analysis of start-up, retention, and adherence in ALS clinical trials. Neurology. 2013 Sep 04;81(15):1350&#x2013;1355. doi: 10.1212/wnl.0b013e3182a823e0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0b013e3182a823e0</ArticleId><ArticleId IdType="pmc">PMC3806927</ArticleId><ArticleId IdType="pubmed">24005339</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O. ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment? Front Aging Neurosci. 2017;9:68. doi: 10.3389/fnagi.2017.00068. doi: 10.3389/fnagi.2017.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="doi">10.3389/fnagi.2017.00068</ArticleId><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference><Reference><Citation>ALS Association  VA Provides Benefits to Veterans with ALS and Families. 2020.  [2021-01-01].  
 http://web.alsa.org/site/PageServer?pagename=va_provides_benefits.?
</Citation></Reference><Reference><Citation>Horton DK, Graham S, Punjani R, Wilt G, Kaye W, Maginnis K, Webb L, Richman J, Bedlack R, Tessaro E, Mehta P. A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013. Amyotroph Lateral Scler Frontotemporal Degener. 2018 Feb;19(1-2):126&#x2013;133. doi: 10.1080/21678421.2017.1406953. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1406953</ArticleId><ArticleId IdType="pmc">PMC5815888</ArticleId><ArticleId IdType="pubmed">29262737</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Pastula D, Welsh E, Pulley D, Cudkowicz ME. Scrutinizing enrollment in ALS clinical trials: room for improvement? Amyotroph Lateral Scler. 2008 Oct;9(5):257&#x2013;65. doi: 10.1080/17482960802195913.794219329</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960802195913</ArticleId><ArticleId IdType="pubmed">18608092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Wicks P, Heywood J, Kasarskis E. Modifiable barriers to enrollment in American ALS research studies. Amyotroph Lateral Scler. 2010 Dec;11(6):502&#x2013;7. doi: 10.3109/17482968.2010.484494.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2010.484494</ArticleId><ArticleId IdType="pubmed">20446890</ArticleId></ArticleIdList></Reference><Reference><Citation>Katyal N, Govindarajan R. Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement. Front Neurol. 2017;8:521. doi: 10.3389/fneur.2017.00521. doi: 10.3389/fneur.2017.00521.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2017.00521</ArticleId><ArticleId IdType="doi">10.3389/fneur.2017.00521</ArticleId><ArticleId IdType="pmc">PMC5626834</ArticleId><ArticleId IdType="pubmed">29033893</ArticleId></ArticleIdList></Reference><Reference><Citation>Malek AM, Stickler DE, Antao VC, Horton DK. The National ALS Registry: a recruitment tool for research. Muscle Nerve. 2014 Nov;50(5):830&#x2013;4. doi: 10.1002/mus.24421. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24421</ArticleId><ArticleId IdType="pmc">PMC4206601</ArticleId><ArticleId IdType="pubmed">25111654</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  National ALS Registry. 2020.  [2021-01-01].  
 https://www.cdc.gov/als/
</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention  ALS Research Notification for Clinical Trials and Studies.  [2021-01-01].  
 https://www.cdc.gov/als/ALSResearchNotificationClinicalTrialsStudies_Active.html
.</Citation></Reference><Reference><Citation>Skiba MA, Bell RJ, Islam RM, Davis SR. Challenges in recruitment to an epidemiological study of young Australian women: the Grollo-Ruzzene Foundation Young Women's Health Study. Aust N Z J Public Health. 2019 Apr;43(2):131&#x2013;136. doi: 10.1111/1753-6405.12868.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1753-6405.12868</ArticleId><ArticleId IdType="pubmed">30727023</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Westeneng H, Nikolakopoulos S, Verhagen IE, van Es MA, Eijkemans MJC, van den Berg LH. Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials. Neurology. 2019 Jan 09;:e451&#x2013;e460. doi: 10.1212/WNL.0000000000006855. 
 
WNL.0000000000006855</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000006855</ArticleId><ArticleId IdType="pmc">PMC6369899</ArticleId><ArticleId IdType="pubmed">30626653</ArticleId></ArticleIdList></Reference><Reference><Citation>New Eligibility Criteria Needed for ALS Clinical Trials. 2019. Jan 31,  [2021-01-01].  
 https://www.neurologylive.com/view/new-eligibility-criteria-needed-for-als-clinical-trials
.</Citation></Reference><Reference><Citation>Govindarajan R, Berry JD, Paganoni S, Pulley MT, Simmons Z. Optimizing telemedicine to facilitate amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020 Sep;62(3):321&#x2013;326. doi: 10.1002/mus.26921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26921</ArticleId><ArticleId IdType="pubmed">32415876</ArticleId></ArticleIdList></Reference><Reference><Citation>Tuttle KR. Impact of the COVID-19 pandemic on clinical research. Nat Rev Nephrol. 2020 Oct;16(10):562&#x2013;564. doi: 10.1038/s41581-020-00336-9. 
 
10.1038/s41581-020-00336-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-020-00336-9</ArticleId><ArticleId IdType="pmc">PMC7404075</ArticleId><ArticleId IdType="pubmed">32760016</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan Thomas. A Tough Road: Cost To Develop One New Drug Is $2.6 Billion; Approval Rate for Drugs Entering Clinical Development is Less Than 12%. 2019. Mar 21,  [2021-01-01].  
 https://www.policymed.com/2014/12/a-tough-road-cost-to-develop-one-new-drug-is-26-billion-approval-rate-for-drugs-entering-clinical-de.html
.</Citation></Reference><Reference><Citation>Pateria Dinesh, Singh Rahul.  Cognizant 20-20 Insights. Teaneck, NJ: Cognizant; 2015. Aug,  [2021-01-01]. Patients Recruitment Forecast in Clinical Trials. 
 https://www.cognizant.com/whitepapers/patients-recruitment-forecast-in-clinical-trials-codex1382.pdf
.</Citation></Reference><Reference><Citation>Reynolds T. Clinical trials: can technology solve the problem of low recruitment? BMJ. 2011 Jun 14;342:d3662. doi: 10.1136/bmj.d3662.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d3662</ArticleId><ArticleId IdType="pubmed">21672994</ArticleId></ArticleIdList></Reference><Reference><Citation>Massachusetts General Hospital  Healey ALS Platform Trial.  [2021-01-01].  
 https://www.massgeneral.org/neurology/als/research/platform-trial
.</Citation></Reference><Reference><Citation>Mehta P, Kaye W, Bryan L, Larson T, Copeland Timothy, Wu J, Muravov O, Horton K. Prevalence of Amyotrophic Lateral Sclerosis - United States, 2012-2013. MMWR Surveill Summ. 2016 Aug 05;65(8):1&#x2013;12. doi: 10.15585/mmwr.ss6508a1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.ss6508a1</ArticleId><ArticleId IdType="pubmed">27490513</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Cudkowicz ME, Windebank AJ, Staff NP, Owegi M, Nicholson K, McKenna-Yasek D, Levy YS, Abramov N, Kaspi H, Mehra M, Aricha R, Gothelf Y, Brown RH. NurOwn, phase 2, randomized, clinical trial in patients with ALS. Neurology. 2019 Nov 18;93(24):e2294&#x2013;e2305. doi: 10.1212/wnl.0000000000008620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000008620</ArticleId><ArticleId IdType="pmc">PMC6937497</ArticleId><ArticleId IdType="pubmed">31740545</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson Terry D, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Hall M, Kittle G, Eydinov M, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, St Pierre ME, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Yu Z, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve. 2021 Jan;63(1):31&#x2013;39. doi: 10.1002/mus.27091. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.27091</ArticleId><ArticleId IdType="pmc">PMC7820979</ArticleId><ArticleId IdType="pubmed">33063909</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan MH, Thomas M, MacEachern MP. Using registries to recruit subjects for clinical trials. Contemp Clin Trials. 2015 Mar;41:31&#x2013;8. doi: 10.1016/j.cct.2014.12.012. 
 
S1551-7144(14)00197-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cct.2014.12.012</ArticleId><ArticleId IdType="pmc">PMC4380621</ArticleId><ArticleId IdType="pubmed">25545027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>